Extra-cellular adenosine generated by circulating CD39+ Tregs of cancer patients not only inhibits anti-tumor responses and stimulates vascular endothelial cell proliferation, but also reduces monocyte ability to activate the endothelium, limiting migration of effector T-cells into the tumor (55–58). The gene discussed is ENTPD1; the disease is neoplasm.